147 related articles for article (PubMed ID: 8798979)
1. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.
Londos-Gagliardi D; Dalibart R; Geoffre S; Dalbon P; Pouliquen JF; Georges-Courbot MC; Sainte-Foie S; Hajjar C; Georges AJ; Moreau JP; Guillemain B
AIDS Res Hum Retroviruses; 1996 Jul; 12(10):941-50. PubMed ID: 8798979
[TBL] [Abstract][Full Text] [Related]
2. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
3. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
5. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG; Rowe J; Foung SK
J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
[TBL] [Abstract][Full Text] [Related]
6. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
7. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG; Yang Q; Rowe J; Foung SK
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
[TBL] [Abstract][Full Text] [Related]
8. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
[TBL] [Abstract][Full Text] [Related]
9. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
10. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I.
Edouard E; Londos-Gagliardi D; Busetta B; Geoffre S; Dalbon P; Moreau JP; Guillemain B
Leukemia; 1994 Apr; 8 Suppl 1():S65-7. PubMed ID: 8152306
[TBL] [Abstract][Full Text] [Related]
11. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
[TBL] [Abstract][Full Text] [Related]
12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
13. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
14. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
[TBL] [Abstract][Full Text] [Related]
15. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
[TBL] [Abstract][Full Text] [Related]
16. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
[TBL] [Abstract][Full Text] [Related]
17. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
[TBL] [Abstract][Full Text] [Related]
19. Development and Evaluation of a Novel ELISA for Detection of Antibodies against HTLV-I Using Chimeric Peptides.
Mosadeghi P; Heydari-Zarnagh H
Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):144-150. PubMed ID: 29757587
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
Jacobson S; Reuben JS; Streilein RD; Palker TJ
J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
